Kraus PH - Search Results

1

Age at onset of Huntington disease is not modulated by the R72P variation in TP53 and the R196K variation in the gene coding for the human caspase activated DNase (hCAD).

Arning L, Kraus PH, Saft C, Andrich J, Epplen JT. Arning L, et al. Among authors: kraus ph. BMC Med Genet. 2005 Oct 3;6:35. doi: 10.1186/1471-2350-6-35. BMC Med Genet. 2005. PMID: 16202123 Free PMC article.

2

NR2A and NR2B receptor gene variations modify age at onset in Huntington disease.

Arning L, Kraus PH, Valentin S, Saft C, Andrich J, Epplen JT. Arning L, et al. Among authors: kraus ph. Neurogenetics. 2005 Feb;6(1):25-8. doi: 10.1007/s10048-004-0198-8. Epub 2004 Nov 17. Neurogenetics. 2005. PMID: 15742215

3

No association between polymorphisms in the BDNF gene and age at onset in Huntington disease.

Mai M, Akkad AD, Wieczorek S, Saft C, Andrich J, Kraus PH, Epplen JT, Arning L. Mai M, et al. Among authors: kraus ph. BMC Med Genet. 2006 Nov 10;7:79. doi: 10.1186/1471-2350-7-79. BMC Med Genet. 2006. PMID: 17096834 Free PMC article.

4

NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner.

Arning L, Saft C, Wieczorek S, Andrich J, Kraus PH, Epplen JT. Arning L, et al. Among authors: kraus ph. Hum Genet. 2007 Sep;122(2):175-82. doi: 10.1007/s00439-007-0393-4. Epub 2007 Jun 14. Hum Genet. 2007. PMID: 17569088

5

ASK1 and MAP2K6 as modifiers of age at onset in Huntington's disease.

Arning L, Monté D, Hansen W, Wieczorek S, Jagiello P, Akkad DA, Andrich J, Kraus PH, Saft C, Epplen JT. Arning L, et al. Among authors: kraus ph. J Mol Med (Berl). 2008 Apr;86(4):485-90. doi: 10.1007/s00109-007-0299-6. Epub 2008 Mar 8. J Mol Med (Berl). 2008. PMID: 18327563

6

Apolipoprotein E genotypes do not influence the age of onset in Huntington's disease.

Saft C, Andrich JE, Brune N, Gencik M, Kraus PH, Przuntek H, Epplen JT. Saft C, et al. Among authors: kraus ph. J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1692-6. doi: 10.1136/jnnp.2003.022756. J Neurol Neurosurg Psychiatry. 2004. PMID: 15548484 Free PMC article.

7

Hyperhomocysteinaemia in treated patients with Huntington's disease homocysteine in HD.

Andrich J, Saft C, Arz A, Schneider B, Agelink MW, Kraus PH, Kuhn W, Müller T. Andrich J, et al. Among authors: kraus ph. Mov Disord. 2004 Feb;19(2):226-8. doi: 10.1002/mds.10629. Mov Disord. 2004. PMID: 14978683

8

Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease.

Saft C, Zange J, Andrich J, Müller K, Lindenberg K, Landwehrmeyer B, Vorgerd M, Kraus PH, Przuntek H, Schöls L. Saft C, et al. Among authors: kraus ph. Mov Disord. 2005 Jun;20(6):674-9. doi: 10.1002/mds.20373. Mov Disord. 2005. PMID: 15704211

9

[Amisulpride in Huntington's disease].

Saft C, Andrich J, Kraus PH, Przuntek H. Saft C, et al. Among authors: kraus ph. Psychiatr Prax. 2005 Oct;32(7):363-6. doi: 10.1055/s-2003-815024. Psychiatr Prax. 2005. PMID: 16220421 German.

10

Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.

Saft C, Lauter T, Kraus PH, Przuntek H, Andrich JE. Saft C, et al. Among authors: kraus ph. BMC Neurol. 2006 Feb 28;6:11. doi: 10.1186/1471-2377-6-11. BMC Neurol. 2006. PMID: 16507108 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters